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The bioeconomy is a strategic program strongly promoted within OECD countries. This
paper discusses an example of how the purposes and promises of the bioeconomy are
enacted in Brazil, in line with local environmental and political specificities. We focus on
scientific and political discourse portraying a technological solution to tackle dengue
disease as a public health problem. The technology involves genetically modified mos-
quitoes that are released into the environment in order to suppress populations of disease-
carrying mosquitoes. We show how the promise of tackling dengue, through technical and
scientific arguments, becomes connected to political discourse about the welfare and
‘progress’ of Brazil as a nation. We argue that this connection comes about through two
types of rhetoric devices that downplay risk and uncertainties in favor of the promises
inscribed in laboratory-bred mosquitoes. In line with a basic tenet in the field of Science
and Technology Studies, it becomes clear that science and politics are intertwined in both
discourse and practice. In addition, we highlight the experimental and political character
of public health interventions from a spatial perspective. The mosquitoes are set free in an
environment that is considered a natural environment while at the same time responding
to certain laboratory conditions such as relative isolation. In addition, the genetically
modified mosquitoes, as bio-objects, are expected to act like natural mosquitoes in the
wild. With these types of proximity between technology and nature in mind, we argue that
the mosquitoes are meant not only to enact the pest management program they have been
designed for, but also a political program claiming an avant-garde position of Brazil in a
global bioeconomy.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
In the face of a range of environmental, economic and
social challenges, both large amounts of money and high
hopes are invested in technological solutions. Within OECD
countries, technological innovation is a key priority, and a
strategic program has been elaborated through the concept
of the “knowledge-based bioeconomy” [1]. In such bio-
economy a substantial share of economic output is
dependent on the development and commercialization ofis-Castro).
. All rights reserved.biological materials through technological innovation [2].
According to this model, cutting-edge and competitive
biotechnology is to be developed by promoting close col-
laborations between universities and industry, and their
joint mission is held to be “serving the dual purpose of
creating wealth and improving quality of life” [3]. The
expansion of the bioeconomy has been strongly promoted
within OECD countries [4]. This may explain why most
studies tend to limit themselves to examine and discuss
ongoing developments within those countries, although
the bioeconomy’s strategic program is not limited to this
part of the world.
Together with other articles in this Special Issue, this
paper aims at discussing biotechnology and bioeconomy
3 Other laboratories were also working on this type of system as
L. Reis-Castro, K. Hendrickx / Technology in Society 35 (2013) 118–128 119outside the “charmed circle” of OECD countries [5],
focusing on case studies from Latin America. Indeed, it is
interesting to study the existing contrasts and similarities
with OECD countries, but there is more to that: an in-depth
analysis of current cutting edge biotechnology-related
innovations in Latin America also stresses different
research objects and their related discourse, which are of
foremost importance for STS scholarly research. In this
paper, the case study we will introduce is a particular
matter: genetically modified mosquitoes (GMMs).1 We
find it particular for two reasons. Firstly, genetically or
otherwise engineered animals have received much less
attention worldwide than transgenic crops. With the
exception of experiments that have become iconic by their
sheer visibility or potential to arouse reactions, such as
‘Dolly’, the cloned sheep, or the Vacanti mouse with a
human ear attached to it (also known as the earmouse),
laboratories over the world are populated with bio-
technologically engineered animals with a more anony-
mous and ambiguous status than those public icons with
an outspoken science fiction or ‘freak’ dimension. We are
interested in how these animals become discursively
associated to scientific progress, public health and national
welfare. We begin by explaining the technology in itself
and the releases of GM mosquitoes in open field trials in
Brazil (Section 2). Then, in Section 3, we take a closer look
at how the genetic technology is presented by the pro-
moters of the technology in scientific publications and
websites. In scientific discourse about genetically modified
mosquitoes, it becomes clear that their abnormality is
played down by inserting them in a genealogy of former
technological developments on the one hand, and that
their ‘ordinariness’ is upgraded by inscribing them with
promises for public health address the issue of dengue
fever. We will discuss this by drawing on the concept of
ordinary treasures [6]. At the same time we will discover
another particularity of the mosquitoes: they move
beyond the confinements of the laboratory, thereby
extending its boundaries. They are released into the ‘wild’.
In the fourth section, wewill discuss the GMmosquitoes as
part of a larger debate on GMOs, stem cell research and a
particular rhetoric of hope in present-day Brazil. In the
final discussion section we explain that both scientific
discourse and Brazil’s rhetoric of hope are connected
through the promises of a new technology – promises that
in our case become embodied by a mosquito.pointed out in the article written by Oxitec’s researcher [9]; (see also Ref.
[57]). Oxitec has two types of RIDL approach: the bisex and the female
specific RIDL. They have a similar working mode but on the latter the
system has the specificity to induce repressible female-specific lethality
[33]. All the releases of GM insects conducted until now were bisex.
Besides the transgenic mosquito Ae. aegypti, another Oxitec bisex RIDL
insect has been released before the GM mosquitoes. This first release of
GM insects was done in order to deal with an agricultural pest in2. The releases of genetically modified mosquitoes2
Recently there has been an increase of activities con-
cerning transgenic insects. The most notorious events
have been the open field trials of genetically engineered1 The terms ‘genetically modified’ and ‘transgenic’ are not synonymous,
the latter being more specific and referring to the introduction of genes
from other species. Any transgenic species is genetically modified, but the
reverse doesn’t necessarily apply. The GMM is both and we use the two
terms alternatively.
2 The case study on the genetically modified mosquito in Brazil has
primarily been conducted by Luisa Reis-Castro, in the framework of her
previous researches. For more information see Ref. [56].mosquitoes occurring since 2009. All the transgenic
insects released in the environment are a product of the
British company Oxitec – the Oxford Insect Technologies,
a spin-off company from Oxford University. In this sec-
tion we explain why these GMOs are being set free and
how this mosquito-technology works. Up to now, mos-
quitoes have been released in the Cayman Islands, in
Malaysia, and in Brazil. We will focus on the Brazilian
releases that have been the most important in scale and
scope.
2.1. Why GM mosquitoes?
The GMMs have been developed as a technological
solution to tackle dengue fever disease. There has been a
worldwide increase in cases and outbreaks of dengue. The
World Health Organization considers it the most rapidly
spreading mosquito-borne viral disease in the world,
turning it into a public health emergency of international
concern [7].
The vector for dengue – i.e. the mosquito transmitting
the disease – is the Aedes aegytpi, which can also be the
vector for avian malaria and yellow fever viruses [8]. The
released GMM technology aims to reduce the number of
dengue cases, by targeting the vector of the disease: the
population of Ae. aegypti in its natural habitat. The British
biocompany Oxitec has developed the Release of Insects
Carrying a Dominant Lethal (RIDL) system.3 The RIDL
strategy is part of GM pest management approach that
aims for population suppression, containment or erad-
ication.4 In a nutshell, the Ae. aegypti population is to be
reduced by releasing genetically modified counterparts
that contain conditionally lethal genes. These GM mos-
quitoes will mate with the wild ones and produce an off-
spring that should die before adulthood.
The core of the RIDL system is the protein tetracycline-
repressible (tTA) transcription5 [9]. In a few words, it con-
ditions the insects to only survive to adulthood if in the
presence of the antibiotic tetracycline. One can still mass
rear these GMMs, since inside the lab the growing insect
can be fed tetracycline.
Only the female Ae. aegypti bites for blood in order to
mature the eggs. This means only females transmit denguecotton farming. Open-field experiments of a genetically modified pink
bollworm – the OX1138 – were conducted during three years in Yuma
County, Arizona, USA. Preliminary field releases with OX1138 were car-
ried out in 2006 and larger-scale ones in 2007 and 2008. Nonetheless,
besides the genetic modification, OX1138 was also irradiated before being
released to guarantee sterility [56].
4 Another approach aims at population transformation or replacement.
Strategies under this group introduce a transformation that reduces or
blocks the insect’s ability to transmit a disease.
5 Also defined as Tetracycline-Controlled Transcriptional Activation.
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RIDL strain Ae. aegypti OX513A. Oxitec proposes to release
OX513A males, which would compete with their wild
counterparts. The lab GMMs are homozygous6 for the lethal
gene, and the latter is a dominant one. That means that the
offspring of GM males with wild females will be hetero-
zygous7 for the lethality and will still express it. Some
promoters of this technology define these offspring as the
“doomed heterozygotes” [10].
The sex-separation of the bisex OX513A strain is done
mechanically. The criterion for sorting them is the size dif-
ference between male and female [11]. Nevertheless, in an
article where some of the authors are researchers from the
British company Oxitec it is acknowledged that sex sepa-
ration based on pupal size contains a small error margin,
from less then 1% female to 0.1%, if larger males are also
discarded [10]. Thismight seem a small percentage, but on a
large scale the error margin becomes consequential: some
females are inevitably also being released.
Furthermore, although Oxitec defines its product as
sterile, the heterozygotes survive through larvae phase but
should not reach adulthood. That is, they are characterized
by late-lethality. An article written by Oxitec’s researchers
acknowledges a 3–4% survival rate to adulthood of the het-
erozygotes in lab experiments [10]. Numbers could be even
higher in case tetracycline is present in the environment.8 A
confidential Oxitec report made public by NGO GeneWatch
UK showed a 15% survival, most probably because the larvae
were being fed cat food contaminated with tetracycline in
the laboratory (for the report see Refs. [12]; for Oxitec’s
response see Refs. [13,14]. In sum, the successful imple-
mentation of the technology is not straightforward but
depends on a number of factors such as a correctmechanical
sex-separation and a survival rate of the heterozygotes as
close as possible to 0%. In the final section of this paper, we
will return to the problem of evaluating an implementation
as ‘successful’, or a technology as ‘working’. Before that,
we have to sketch a larger picture of the GM mosquito
technology and its embedding in society, starting with the
releases of these mosquitoes in the environment.2.2. Brazilian releases and the problem of dengue
Oxitec’s OX513A has been released in three different
locations, with the experiments being conducted by local
institutes. The first field trial of GMMs happened in the
Cayman Islands,9 a British Overseas Territory. The second
release happened in Malaysia and was carried out by the
local Institute for Medical Research (IMR). In Brazil,
researchers from Universidade de São Paulo (USP) are6 The two alleles of the gene are identical.
7 The two alleles of the gene are different.
8 Tetracycline is “an antibiotic used to treat bacterial infections such as
urinary tract infections, chlamydia and acne” [58].
9 Some have suggested that the choice of locating these releases at the
Cayman Islands was due to its biosafety considerations being not well
developed [59]. There is a gap in the legislation: the Cayman Islands are a
non-party of the Cartagena Biosafety Protocol because UK’s ratification is
not extended to its overseas territories (for more information on this legal
controversy see Ref. [60]).responsible for carrying out the trials. The Social Organ-
ization10 Moscamed is responsible for mass rearing the
mosquitoes; it is located in Juazeiro, in the state of Bahia, the
same location where the first Brazilian experiments were
conducted. Moscamed already worked with insects on a
large scale, developing fruit flies (Ceratitis capitata) sterilized
through irradiation. In September 2009, the request to
import three batches of five thousand embryos from Oxitec
was approved by the Brazilian National Technical Commis-
sion for Biosafety (Comissão Técnica Nacional de Bio-
ssegurança/CTNBio) [15]. CTNBio is the institution assigned to
assess the safety of requests concerning the use of all types of
genetically modified organisms in the country. In December
2010, the request for a planned release of GMMs into the
environment was authorized [16].
In February 2011, the first phase was carried out: some
releases in smaller numbers to evaluate the transgenic
mosquito behavior. In April, the second phase started, with
larger releases up from 50,000 up to 100,000 mosquitoes
per week [17]. The general information provided by the
Brazilian media was that the releases would be conducted
in five locations around Juazeiro, in the Bahia state, during
an eighteen-month period throughout 2011 and 2012
(e.g. Refs. [18,19]). In March 2012, a workshop was organ-
ized to discuss the project’s progress. According to the
report presented in this workshop, the conducted releases
only happened in one of the locations near Juazeiro (the
suburb of Itaberaba). One of the authors contacted Professor
Margareth Capurro, the project coordinator, and she
informed us by email that contrary towhat had been said in
themedia, “Itaberaba is only the first year project. Two new
locations are scheduled for the second year of the project.
Mandacaru already started inMarch. The project is at least 3
years long”.11 In May, the government of the Brazilian state
of Tocantins announced that it would also adopt genetic
mosquitoes as a strategy to tackle dengue disease [20].
Among the three locations, Brazil is the onlyonewhere the
transgenicmosquitoes are still currently being set free. It is by
far the largest release in scale with more than fifteen million
insects released between 2011 and 2012 [21]. Moreover, the
GMMproject seemstocontinueandexpand, as thereareplans
to increase its scale, with announcements of new release
locations and the construction of a new Production Unit of
Transgenic Aedes (UPAT) that can mass rear four million
mosquitoes perweek [22]. Furthermore, it is also important to
point out that in Brazil dengue is considered a very serious
public health issue. The issue is considered severe, mainly
because of the geographical spread of the disease, present in
all 27 states of the countryor3794municipalities [23], and the
recent increase of cases of dengue hemorrhagic fever (DHF)
since the 1990s. Dengue fever becomes fatal if it develops into
DHF. However, in Brazil the morbidity rates of DHF are rela-
tively low: during the 1990s, the proportion of DHF cases
attained 0.06%, and this percentage has gone up to 0.3% in10 In Brazil, to be a social organization means that the company can sell
its products and services and make profit, but all has to be reinvested
back into the business. As a social organization Moscamed is linked to the
Ministry of Agriculture, Livestock and Supply (MAPA).
11 M. Capurro, personal communication, April 4, 2012.
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still considered relatively low as compared to Southeast Asia.
DHF lethality has varied in Brazil from 1.45% (1995) to 11.25%
(2007) [24]. The case-fatality DHF can typically be dealt by
trained physicians, since “access to health practitioners who
are trained to identify DHFand treat its effects can reduce that
rate to about 1%” [25]. Dengue costs an estimated amount of
one billion reais– approximately 400million euros – annually
to Brazilian public funds [26].
3. Genetically modified mosquitoes as Ordinary
Treasures . Flying around
In this section we examine how the researchers from
Oxitec present their mosquito-technology, by exploring the
shifts of interpretative repertoire in their articles. We groun-
ded this analysis on the concept of ordinary treasure from
Holmberg and Ideland [6] in their studyof another genetically
engineered animal, the lab mouse. When analyzing trans-
genic mice used in laboratory experiments, Holmberg and
Ideland noted a tension in the discourse of lab workers and
members of ethical committees. They concluded that GM
animals “are framed as normal, ordinary and thereby
unproblematic on the one hand, and as valuable treasures in
which are embedded hopes and expectations of future
medical treatments on the other” [6]. The authors observe
shifts in the interpretative repertoire – i.e., a shift in the set of
explanatory statements used to describe them – made
through different categories of rhetorical comparison. For
them, these shifts construct the transgenic labmice as normal
and ordinary and at the same time treasures filled with future
medical expectations. According to Holmberg and Ideland,
this flexible use of terms and concepts related to normality on
the one hand and novelty on the other, has the discursive
effect of making only certain aspects visible, while others are
excluded and become hidden or silent. Promises related to
technological innovation are emphasized, while uncertainties
concerning transgenetics are downplayed through rhetorical
comparison with genetic processes in cross-breeding or nat-
ural selection. These shifts between repertoires about ordi-
nariness and treasured novelty contribute to the construction
of what Holmberg and Ideland call transgenic silences. In the
case of laboratorymice, scientific uncertainty, the suffering of
animals, human agency, and responsibility become ‘ethical
non-issues’.When looking at the comparisonsmade between
genetic modification and irradiation, or GM and wild mos-
quitoes, we observe very similar discursive shifts in the pro-
motion of the GMM technology.
3.1. Genetic modification compared to irradiation
Promoters of the OX513A tend to describe the
mosquito-technology in a dichotomous manner. Usually
they present the Release of Insects Carrying a Dominant12 Interestingly, an article entitled ‘Why RIDL is not SIT’ and one of the
authors isOxitec’s researcher LukeAlphey, has just argued the opposite: that
RIDL is not SIT [61]. Nevertheless, in this article they only discuss the other
type, the female specific RIDL. The arguments used to declassify Release of
Insects Carrying aDominant Lethal as SITare only valid for the latter, and not
for the bisex strain – which is the one we have been discussing.Lethal (RIDL) bisex strain as a continuation (e.g. Refs.
[8–10,27])12 or a variant (e.g., [28]) of the Sterile Insect
Technique (SIT).
The SIT is a pest management technique that aims at
diminishing the size of the pest population. Reproductive
sterility can be induced in different ways, such as chemicals
or the more commonly used ionizing radiation method.
The approach means that these sterile insects are released
in large numbers; the males will mate with wild females,
but will produce no viable offspring. Continuous releases
must be done to effectively reduce population over several
generations [29].
When presenting the RIDL OX513A, promoters of this
mosquito-technology usually highlight the already estab-
lished history of the Sterile Insect Technique and some of its
successful cases. For example, Luke Alphey, the chief sci-
entific officer and one of Oxitec’s founders, starts his article
Re-engineering the sterile insect technique presenting all the
advantages from SIT and describing cases where it has been
successfully adopted [9]. In Beech et al., where all authors
are from Oxitec, they argue that
Genetics-based insect control strategies, based on the
classical Sterile Insect Technique (SIT), are becoming
increasingly viable. The close affinity to established SIT
and biological control methods means that there is a
large body of experience on which to draw when using
GM insects in this way [30].
In this sense, the Release of Insects Carrying a Dominant
Lethal approach would not be something novel, but just a
continuation of the already long used SIT.
Nevertheless, at the same time, they distance themselves
from ‘classical’ irradiation-based Sterile Insect Technique.
After highlighting the advantages and the long history of
SIT, the disadvantages are pointed out, as for example:
Despite its environmental benefits, SIT has been used
against only a rather modest number of target species.
This is in large part due to a fundamental problem with
the system. The released insects are required to compete
for mates with wild insects. The production process,
however, and in particular the need to sterilize the
insects by irradiation, causes a dramatic loss of com-
petitive mating ability relative to wild type. Irradiated
insects are less competitive and also have reduced life
spans [9].
In this context, the RIDL genetically engineered approach
is presented as maintaining the advantages from ‘classical’
SIT and at the same time overcoming its weaknesses. They
claim that “with the advent of modern biotechnology it
becomes possible to improve the applicability, efficacy,
safety and efficiency of the SIT” [8]. Thus, concomitantly to
being part of SIT as an ordinary and established approach, it
becomes a new and innovative treasure for pest manage-
ment and public health policies. By keeping SIT as a fixed
point of comparison, the ‘trans’-matter is not problematized,
but merely a technical issue in the background: nothing
really changes, but the GMM’s will simply perform better.
This tension between shifting repertoires of being or not
SIT can be noticed in other technical characteristics of the
mosquito-technology. Beech et al. argue that
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of a self-limiting approach. (.). This approach builds on
the operational precedents established by the successful
use over 50 years of radiation-sterilised (non-GM)
insects to control certain agricultural pest insects,
known as Sterile Insect Technique (SIT) [30].
The word “sterile” is used with inverted commas
because the irradiated SIT insects are sterile, whereas the
RIDL insects are not. As mentioned before, the RIDL
mosquitoes produce offspring that can only survive in the
presence of the antibiotic tetracycline. If this antibiotic is
not present in the natural environment, the wild larvae
should not reach adulthood. In an interview, the
researcher responsible for the Brazilian releases, Mar-
gareth Capurro, pointed out that difference and high-
lighted that she does not agree with calling the RIDL
OX513A sterile.13
Having in mind this distinction, it is interesting to point
out the shifts between including the OX513A as SIT or not.
For example, Phuc et al. – where several are Oxitec
researchers – argue that the RIDL approach is better and
should substitute SIT. As mentioned in Section 3, not all
heterozygotes die before adulthood, with a 3–4% survival
rate in lab experiments. In order to justify this “incomplete
penetrance of lethality”, Phuc et al. cite the work of H.J.
Barclay who “concluded that moderate levels of non-
sterility, e.g. 8%, would have little adverse effect” on the
effectiveness of the suppression program [10]. The work of
Barclay, however, is about mosquitoes irradiated with the
SIT technique, and not the genetically engineered RIDL
insects [31]. This example evidences the shift between
being part of the SIT, and thus adopting its standards, or
being something different. The net result is that uncer-
tainties are downplayed by discursively putting RIDL in the
prolongation of SIT, while the novelty and performance of
RIDL are emphasized by distinguishing it from SIT. When
analyzing mice used in laboratory experiments, Holmberg
and Ideland also noted these shifts of interpretative rep-
ertoire in the discourse of lab workers and members of
ethical committees. Holmberg and Ideland show that GM
mice are presented as a continuation of older techniques,
such as cross-breeding, while being invested with hope for
medical applications, because of the scientific break-
through these mice come to stand for at the same time.3.2. GM mosquitoes compared to wild mosquitoes
In the previous paragraph, the GM mosquito, being the
product of a specific technique of genetic modification, was
compared to irradiated mosquitoes, obtained through a
different technique. Next to comparisons between tech-
niques and their outcomes or final products, the GM
mosquitoes are also compared to their wild counterparts,
both male and female. We have already seen that the
transgenic males are different compared to their wild
counterparts, as they should not produce any viable off-
spring. As mentioned before, some blood-sucking GM13 M. Capurro, personal communication, September 17, 2012.females are bound to be released and be present in the
environment as well. Oxitec answers this question by
underlining the distinction between the transgenic and
the wild female mosquito:
Few GM females are likely to survive long enough to
transmit disease: GM females are essentially the same as
wild females, except they are likely to be much shorter
lived. Because the dengue virus takes a long time to
develop in a mosquito to the point where it can be
transmitted, shorter-lived females are less likely to pass
on the disease. So any surviving RIDL females are likely
to be much less dangerous than wild females. [.]
Any released females pass on their ‘sterile’ genes; so
their offspring will not reach adulthood [emphasis
added] [32].
These particularities that distinguish OX513A males and
females transform themosquito into a “new and innovative
solution to controlling the dengue mosquito, Aedes
aegypti” [33], leading to releases of thousands of mosqui-
toes. At the same time the OX513A is also presented as an
ordinary Ae. aegypti. According to Oxitec, their approach
makes use of a ‘natural’ instinct of the male mosquito: its
capacity and desire to find females. The company website
highlights that “the Oxitec solution harnesses the natural
instincts of male mosquitoes to find females in the wild”
[33]. At this point, a distinction must be made between the
discursive framing of the GM mosquito as ordinary on the
one hand, and its functional ordinariness on the other.
Indeed, the transgenic technology can only work if the
transgenic mosquito has the same phenotypical and
behavioral features as its wild counterpart. In this case it
means that the male OX513A has to find females just as an
ordinary Ae. aegypti does. In addition, the male OX513A not
only has to find the female, but also needs to be able to
mate with it. Oxitec claims that females would not dis-
tinguish between their product and the wild Ae. aegypti. On
their website they explain that
With irradiated males, she [female Ae. aegypti] might
[be able to recognize Oxitec’s males] – but that’s the
clever part of using genetic modification; because Oxi-
tec’s insects don’t have to be irradiated, they are fit and
healthy. Like all male mosquitoes, they will naturally
seek out females and mate with them. This means that
Oxitec’s approach will be much more effective than
other treatments, like pesticides, at targeting mosqui-
toes in difficult-to-reach places – people’s homes and
gardens. And [.] they [female mosquitoes] won’t be
able to tell the difference until it’s too late. [emphasis
added] [34].
The transgenic mosquitoes must behave and look like
their wild male counterparts. This is essential, as the GM
mosquitoes are not confined to the laboratory but designed
to fly out. The mosquitoes are not used as subjects of fur-
ther experimentwithin the lab. Many other GM animals are
created as laboratory instruments for further exper-
imentation. The reason of their existence is the generation
of new knowledge within the lab – knowledge that will
serve to design applications. In contrast, themosquitoes are
a living application in itself. They are bred as agents –
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outside of the lab.14 The reason for their existence is not the
generation of knowledge in the first place, but the sup-
pression of dengue as a public health problem. This raises
interesting questions as to the status and the boundaries of
the laboratory: are the boundaries transgressed or rather
extended? Where does scientific experimentation stop,
and where do public health policies begin? The term ‘open
field trial’ neatly captures the ambiguity of the lab’s
boundaries. The ‘isolated’ aspect of the chosen areas are
also emphasized and seen as a necessity for the functioning
of the project [35]. In the case of transgenic mice, a com-
parison with GM crops out in the environment enable the
researchers to put forward the laboratory as a closed system
and a ‘guarantee against negative ecological effects’ [6].
This is not possible in the case of transgenic mosquitoes. In
fact, the phenomenology of the GM mosquito has certain
features in commonwith that of GM crops: first, both types
of product are designed as a solution or application to be
implemented outside of the laboratory, although the
commercial circuits of transgenic mosquitoes may remain
more restricted than GM crops, available to individual
farmers. Second, their difference to natural counterparts
raises issues of uncertainty and possible adverse ecological
effects. Third, both transgenic crops and mosquitoes must
look and act like their natural counterparts, while playing
out the advantages of their difference as discretely as
possible. In what follows, we will discuss another common
feature between the transgenic mosquito technology and
transgenic plant technology: the technological fix that
these technologies propose, and the political and economic
stakes this creates. Different contributions to this Issue
discuss how the promises of transgenic crops, such as soy
and cotton, have created important political and economic
alliances, initiatives and infrastructures. As the transgenic
mosquito technology is only at the stage of (open) field
trials, we cannot speculate upon the consequences of a
broader application or commercialization. As in the pre-
vious sections, we will limit ourselves to explore the dis-
cursive positioning of the transgenic mosquito, and how
Oxitec’s technology has been received in Brazil. By looking
at how the mosquito technology is narrated, we will dis-
cover how the promises of the transgenic mosquito have
come to be related to the progress of an entire nation.15 Popular uprising which occurred as a reaction to the attempt from4. The embeddedness of ordinary treasures in the
rhetoric of hope and scientific progress
The introduction of genetically engineered organisms in
Brazil has someparticularities thatdeserve to behighlighted
to further develop our case study. From 1995 to 2004 there
was a dispute within the country on the question of who
should be authorizing/prohibiting and regulating the
research, release and commercialization of transgenic14 Another transgenic animal that is also present outside the lab is the
fluorescentfishGloFish. Itwas developedby ZhiyuanGong, at theNational
University of Singapore, as a strategy to monitor water quality. There is a
link between color genes and the genetic elements that respond to pollu-
tants. Since 2003 it has been available in USA market as a fish pet [62].organisms in Brazil. The Brazilian Institute of Environment
and Renewable Natural Resources (Instituto Brasileiro do
Meio Ambiente e dos Recursos Naturais Renovaveis/IBAMA)
linked to the Environmental Ministry has been responsible
for delivering permits and assessing the environmental
impact of all enterprises and activities in the country since
1981. Meanwhile, the National Technical Commission for
Biosafety (Comissao Tecnica Nacional de Biossegurança/
CTNBio), associated with the Ministry of Science and Tech-
nology, was established in 1995. While IBAMA tended for a
more skeptical and precautionary approach, CTNBio adop-
ted a more pro-transgenic attitude [36].
A new Brazilian Biosafety Bill aimed to settle this dis-
pute. A key point is that this bill dealt not only with the
issue of genetically modified organisms, but also with stem
cell research. This fact had a strong impact on how trans-
genic organisms were framed in Brazil.́
̃ ́
4.1. GMOs in Brazil and the rhetoric of hope
In the framework of dealing with stem cells and GMOs
together, there was a discursive and political alliance
between the groups that advocate in favor of these two
technologies. It was common in their arguments to bring
forward historical events to illustrate how sometimes sci-
entific development is not ‘well understood’ or even pun-
ished. The most cited example was of Galileo Galilei and his
incrimination by the Church in 17th century. The Brazilian
example of Oswaldo Cruz and the Vaccine Revolt15 from
1904 in Rio de Janeiro was also frequently mentioned [36].
Another alliance emerged concomitantly: those against
GMOs or those in favor of a more precaution-oriented
approach towards transgenic organisms allied with the
bancada evangélica, the fiercest supporters for banning
stem cells researches. The bancada evangélica is the infor-
mal organization of evangelical parliamentarians whose
lobbying power has grown enormously in Brazil in recent
years.16 Those who advocate against or are skeptical of
GMOs decided to back banning stem-cell research in
exchange of the bancada evangélica’s support on the matter
of genetically modified organisms [37]. As a result of this
second alliance, those who praised for faster liberation of
transgenic and stem cell research could more easily define
their opponents as the forces outside science that attempt
to hold back scientific development.
In this context, GMOs together with the stem cells were
framed as an answer to take Brazil out of the backwardness
and to put it on the path of progress and development.
Stem cell research was presented as a potential cure to a
series of diseases, and transgenic crops as the solution to
the problems of hunger, pest and plague management in
the country. Such associations can be included in whatOswaldo Cruz, then General Director of Public Health to impose man-
datory, universal vaccination against smallpox.
16 Rafael Bruno Gonçalves wrote an interesting paper on how religion
(having in mind the evangelicals) have become an important source of
political recruitment and political identity in Brazil. He highlights that
between 2003 and 2006 seventy evangelical parliamentarians were
elected in the country [63].
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ized vision of the relationship between science and society
which enables its users to project an indefinite range
of science-based technologies into a radically simplified
future where scientific knowledge necessarily extends
control over disease, disability and death” [38]. In addition,
to question the technologies is perceived as a criticism not
only of the promises they contain, but also of their bene-
ficiary: Brazil, wrestling itself out of the backwardness.
The same rhetoric is visible in the genetically engi-
neered Aedes aegypti case, in Brazil and other countries. In
several academic and media articles, before presenting the
mosquito-technology, an account is given of the problem
and severity of dengue fever for public health. STS liter-
ature already points out how skepticism and even mere
questioning about certain technologies are sometimes
labeled as an anti-technology sentiment [39]. Arguments
about the (possible) negative effects of a new technology or
business activity are perceived as a threat to economy and
development [40]. In the case of dengue – as well as other
diseases and starvation – this perception is even stronger,
since being skeptical or against a technology has come to
equal not caring for the suffering people. An example of
such argumentation can be found in a news article about
Oxitec, stating that “the company hopes that it will reduce
populations of disease-carrying mosquitoes by 80% but
public opposition to anything “genetically modified”
remains a significant obstacle to the possibility of saving
thousands of lives” [41].
4.2. Vector control and the double technological fix
Vector control has been the main approach in public
policies dealingwith dengue in Brazil and around theworld
[42]. In other words, the main method to tackle the disease
has been to suppress or eliminate the population of Ae.
aegytpi. Nevertheless, there are controversies concerning
the influence of the mosquito population size in the num-
ber of dengue fever cases [23].
Roriz-Cruz et al. compared two Brazilian neighboring
cities, Rio de Janeiro and Niteroí. Both have similar varia-
bles which would contribute to an elevated Ae. aegypti
infestation rate – usually associated with incidence of
dengue: “(i) vapor pressure (a combined variable of
humidity and temperature), (ii) population density, and (iii)
environmental availability of disposable recipients that
accumulate (rain) water”. Nonetheless,
Though sharing the same climate (vapour pressure¼ 68)
and having similar population density (approximately
4000 people/km2) and sanitation rates, Rio had twice
the dengue incidence (2036 cases per 100,000 inhab-
itants) of Niterói (1038 cases per 100,000 inhabitants) in
2008 [43].
The reason for that, according to the authors, is the
difference between the cities’ primary health care. Looking
again at the two cities, they notice that:
In Niterói, the past 20 years have seen an increase in
primary health care coverage from less than 1 to 77.4%.
This was paralleled by a significant reduction, not onlyin the Aedes aegypti domiciliary infestation rate (from
approximately 10% in 1986 to 1.7% in 2006), but also in
the incidence of dengue cases during these years (from
1383 cases per 100,000 inhabitants in 1986 to 189 cases
per 100,000 inhabitants in 2006). Conversely, only 7.2%
of Rio’s population had primary-care coverage in 2008
(the lowest among Brazilian state capitals), and two
aforementioned dengue indicators have not changed
significantly in the last 20 years (Aedes infestation rate:
from around 10% in 1986 to 7.2% in 2006; incidence:
from 205 cases per 100,000 inhabitants in 1986 to 232
cases per 100,000 inhabitants in 2006) [43].
The authors challenge the argument that vapor pressure
is the best natural predictor for dengue potential (see
Ref. [44]). For them there has been an ecologically biased
approach: the places with high vapor pressure are mainly
located in the so-called developing countries and most of
these do not present a fully implemented and compre-
hensive primary-care system. Thus, they argue that
primary-care system should be the focus of public policies.
Furthermore, Mendonça, Souza and Dutra point the inef-
fectiveness and negligence when it comes to public health
policies and sanitation services as the possible reasons why
the disease keeps coming back in Brazil [45].
Even though there are some controversies, vector control
has been the mainstream approach for dealing with dengue
and other illness transmitted by mosquitoes. This point is
madebyTimothyMitchellwhendiscussing the emergenceof
experts in controlling mosquito-borne diseases at the
beginning of the 20th century. In this case, the experts
focused on malaria and yellow fever. He mentions how ‘bri-
gades’ of uniformed men would attack the mosquitoes with
spray guns and concludes that “disease was to be defeated
not by improved social conditions or medical intervention
but by the physical elimination of the enemy species” [46].
Hence, although it promotes itself as a very innovative
strategy, the RIDL transgenic insect technique follows a
deep-rooted logic that focuses on themosquito, rather than
analyzing and improving social conditions, health care or
medical interventions. This is obvious in the Brazilian case.
The town of Juazeiro in the Northeast state of Bahia – the
chosen location to experiment this cutting edge technology
– does not have running water supply.
This is not just a matter of showing disparities, but it is a
key point, since the female Ae. Aegypti needs to put its eggs
in still water. One inhabitant of Juazeiro points out “What I
know is that, if we had running water supply, things here
would be very different. Without still water that we must
collect for basic things, how can we wash clothes or cook
food? (With running water supply) there would be no
mosquito, from dengue or any type of such diseases” [18].
Margareth Capurro – the USP scientist responsible for
the Brazilian experiments – distinguishes two aspects of the
dengue problem. First, she says that the government does
not provide basic living conditions, such as a running water
system. As a consequence, all houses must have tanks to
collect water, which become breeding sites for the mos-
quito. Second, she points to a lack of responsibility on the
part of individuals. As an example, she mentions that the
Juazeiro municipality distributed plastic covers to put over
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open. Capurro showed pictures of a backyard full of waste
and objects that could potentially be breeding sites.17
Within this framing of the dengue problem, the genet-
ically modified mosquito becomes a double technological fix
within the vector control approach. Alvin Weinberg coined
the concept of “technologicalfix” in the 60s and it is nowpart
of the STS lexicon. It is used to describe technologies that
“eliminate the original social problem without requiring a
change in the individual’s social attitude, or would so alter
the problem as to make its resolution more feasible” [47].
The GMM would allow overcoming two ‘social’ problems: a
government that does not offer basic living conditions – i.e.,
running water and good primary health care – and a pop-
ulation that does not take responsibility in the control of
breeding sites. It becomes a double technology fix; it is nei-
ther the government nor the population that will bring the
solution to the dengue problem, but rather techno-science.
In this sense, the case of the transgenic mosquitoes in Bra-
zil evidences a technological fix that proposes to overcome
not only a problem in the individual attitude or the gov-
ernment’s actions, but an entire deficient infrastructure.4.3. Brazil on the map of vanguard science
In Brazil, it is noticeable that reports on governmental
websites, media articles, and the scientists developing the
technology in the country, link the adoption of the technol-
ogy to Brazil’s international emerging status. Some media
articles have associated the adoption of the transgenic
mosquito with a Brazilian pioneer technological vanguard.18
An example is the statement that “Juazeiro has entered the
map of vanguard science. It has become the first place in the
Americas [sic]19 to free into the wild – in a controlled man-
ner, it should be stressed – genetically modified mosquitoes
to fight dengue” [authors’ translation, emphasis added] [48].
The tendency to point out the national pioneering
technological attitude has been even clearer in the case
of the New Production Unit of Transgenic Aedes (UPAT),
inaugurated July 07, 2012 in Juazeiro, Bahia, the same loca-
tions where the releases had been done. The new ‘bio-
factory’ has 720m2 and the capacity to produce fourmillion
male mosquitoes per week [49]. In several official state-
ments, the large capacity of the factory is emphasized and
confers prestige to the Brazilian nation on the worldwide
scene of scientific development. Here are some examples:
Brazil is pioneer in terms of the dimension of mosquito
production’ affirms the biologistMargareth Capurro, from
the University of São Paulo (USP), coordinator from the
Transgenic Aedes Project (PAT). With the inauguration of
the largest factory of dengue transgenicmosquitoes in the
world, in thebeginningof July, Bahia [statewhere Juazeiro17 M. Capurro, personal communication, September 17, 2012.
18 A very few number of articles related this pioneering activity not with
a vanguard attitude but with the experimental characteristic of the
technology, pointing out how Brazilians are being guinea pigs for the GM
mosquito adoption (for example see Ref. [64]).
19 The first releases were conducted in the Cayman Island, which is also
in the Americas.is located] intends to produce four million insects per
week [authors’ translation, emphasis added] [50].
On the website of the Brazilian government, the
announcement of the New Unit is presented in the fol-
lowing way:
Brazil will produce, on a large scale, transgenic Aedes
Aegypti mosquitoes that will be allies in the fight against
dengue. This Saturday (7) the factorywith the largest sterile
mosquito production capacity worldwide was inaugurated.
(.) The action is unprecedentedworldwide: it is the largest
release of transgenic insects to control the urban dengue
mosquito [authors’ translation, emphasis added] [51].
In the inauguration event of the New Unit, the Minister
of Health, Alexandre Padilha, declared that:
This is a new technology that can become part of the
already adopted techniques for dengue control and it
makes Brazil occupy a place in the production not only of
the [genetically modified] dengue mosquito, but other
types of insects that transmit diseases in the country and
the world [authors’ translation, emphasis added] [22].
The new Production Unit shows that Brazil’s rhetoric of
hope, expressed in terms of technology, science, and
national progress, goes on a par with an active engagement
in the production of GM mosquitoes. In other words: Brazil
is not interested in being just a beneficiary of foreign
technology, but aims at being part of the technological elite.
This enthusiasm is not shared by everyone. Brazilian civil
organizations have emphasized possible risks and the lack
of information about the GMM. In the context of the ‘bio-
factory’ inauguration and its repercussion, several NGOs
published a letter about the transgenic mosquitoes (e.g.,
AS.PTA – Familiar Agriculture and Agroecology; Land of
Rights; Peasant’s Popular Movement). It said that:
Before the method’s efficacy was even tested, these
novel mosquitoes took to national and international
news programs. A newmosquito plant was inaugurated
with pomp and circumstance, before no less than the
Minister of Health and the governor of Bahia, both sur-
rounded by entourages of other authorities. [.] Only a
party-pooper could think of bursting their bubble with
questions about how risky millions of transgenic mos-
quitos might be, released since 2011 into populous
neighborhoods of the city of Juazeiro, Bahia [52]
In the UK, home of Oxitec and where the mosquito was
first designed and bred, there have been accusations that
Oxitec’s choices of locations and releases have been charac-
terized by a colonialist attitude. One of the major voices of
theseaccusationshasbeen the “not-for-profit policy research
and public interest group”, GeneWatch UK. For example,
concerning the first releases of genetically engineered mos-
quitoes in the Cayman Islands, Helen Wallace, the NGO’s
director, argued that “The British scientific establishment is
acting like the last bastion of colonialism, using an Overseas
Territory as a private lab” [emphasis added] [53].
Oxitec has answered these accusations in the same
‘postcolonial framework’. For example, Hadyn Parry, the
company’s chief executive, stated that
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‘using poor regions in the global south, such as cities in
the north east region of Brazil, as its laboratory for
genetically modified mosquitoes’. This insinuation that
we are somehow targeting exploitable populations is
also particularly irksome and patronizing [emphasis
added] [54,55].
He also points out that Oxitec has been “completely
open with the regulators and collaborators”. His argument
is grounded on the basis that
The institutions who determine the acceptability of any
new public health technology are that nation’s regulators.
(.) We are [sic] committed to full transparency in the
regulatory process. This means sharing all research with
these experts, who are in a position where they regularly
evaluate risk–benefit relationships [emphasis added] [54].
While in the UK a debate was initiated in terms of a
colonialist attitude from Oxitec or a patronizing one from
civil organizations such as GeneWatch UK, it is noteworthy
that these issues have not shown up in the Brazilian dis-
cussions. Indeed, as we have noted, the inauguration of the
Production Unit for transgenic Aedes shows that Brazil sees
itself as an active player in the global science community
and not an importer of foreign technology. Criticism of this
ambitious project deals with safety issues, and the lack of
information about the releases and potential hazards20.5. Discussion: bioeconomy and bio-objects enacted
through discourse
The bioeconomy agenda displays a specific way of pre-
senting or narrating the role of biotechnological solutions
in the face of global economic, environmental and public
health challenges. In the bioeconomy, a substantial share of
economic output is dependent on the development and
commercialization of biological materials through techno-
logical innovation. Genetically modified plants are an
example of how biological organisms can become lucrative
economic resources, as several contributions of this Issue
show. We argue that the valuation of biological materials
involves a specific way of portraying these materials and
their related technologies. Discourses on bioeconomy are
not universal, nor free-floating: they are backed up by
actors and institutions and always locally enacted. Through
a case study on transgenicmosquitoes we have been able to
shed some more light on the rhetoric devices of a strategic
program in line with the OECD’s bioeconomy, but analyzed
here in a Brazilian context.
One such rhetoric devicewe identified is the technological
fix: a technological solution is envisioned to the global public
health problem of dengue fever. By proposing a mosquito20 These points have not been made only by NGOs, but by scientists as
well. In the article Scientific Standards and the Regulation of Genetically
Modified Insects, researchers point to a lack of “scientific publication of
experimental data”. They argue that GM technologies cannot progress
without accessible accurate scientific information [65]. In a news article
some Brazilian scientists also expressed their doubts and skepticism
towards the mosquito-technology [66].population suppression program through the release of
GMMs, the vector of dengue disease is emphasized as the
most important cause, leaving other factors backgrounded.
We have stressed that other sources, however, suggest the
importance of primary health care with respect to the
prevalence of dengue. One of the Brazilian releases of GMMs
was conducted in an area without running water, showing
how technological solutions are foregrounded for a disease,
which, as a consequence, seems unrelated to other deter-
minants than the vector of the disease itself. Through the
technological fix, dengue becomes strongly depoliticized
and dependent on technological innovations. Another rhet-
oric device, related to the technological object itself, is the
ordinary treasure. Uncertainties about the technological sol-
ution are downplayed by inscribing it into a genealogy of
former technological developments, suggesting that the
whole constitutes a bodyof generally accepted andmastered
practices. By the same token, the novelty of GMmosquitoes,
like that of GM mice in Holmberg and Ideland’s study,
appears under the guise of hope and promises for a better
future. In the case of Brazil, this ordinary treasure finds itself
embedded in a rhetoric of hope and progress, which is not
only expressed by scientists developing the GMMs, but also
in official and media discourse on the future of an entire
nation. We have put to the fore some particularities of the
Brazilian case which contribute to a better understanding of
how a rather abstract rhetoric of hope takes root in concrete
circumstances. Considering the government’s discourse on
Brazil as a pioneer in GMM technology, and the recent
inauguration of the New Production Unit of Transgenic
Aedes, it becomes clear that such rhetoric is closely asso-
ciated to the defense of science and progress, turning it into a
geopolitical and economic cause. The transgenic mosquito is
to put Brazil on the global scene of vanguard science. The
association of the GMM with Brazil’s position on the world
scene and the emphasis on the productive capacity of the
New Production unit show that the mosquito is not only a
treasured icon of hope, but that it becomes invested with
national prestige.
The transgenic mosquito qualifies as a bio-object. Bio-
objects refer to: “first, new living materials that disrupt
formerly established boundaries and modes of ordering, as
well as, second, to ‘old matters of life’ that are ‘revitalized’
when brought into new spaces”.21 We might add that the
‘new’ and the ‘old’ become ambiguous categories in the
portrayals of the transgenic mosquito. Depending on the
issue at hand, the mosquito is like anymosquito, or it is not.
Accordingly, the laboratory has different ‘faces’ ranging
from a production site of an extraordinary bio-object or
product, to an experimentation site extending into the
natural environment, where the ‘product’ is released and
where its extraordinary character must go unnoticed. Like
GM plants, the laboratory-reared mosquito is ‘set free’ to
occupy new spaces. However, the technological and func-
tional requirement is that the mosquitoes must deploy
their difference in a discrete manner, in order to outwit
their wild female counterparts and attain the objectives21 The definition of bio-objects can be found at http://www.univie.ac.at/
bio-objects/bioobjects.htm. For more information also see Ref. [67].
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transgenic silence seems to have a visual counterpart,
which is not rhetoric but essential to make the technology
work. However, if the ‘working’ of a technology is seen in a
larger picture that is not only ‘purely’ technical, but related
to the cooperation of non-human actors (mosquitoes) and
to its embedding in society (see van Zwanenberg and Arza,
this issue), one may well ask to what extent the discursive
framing and functional characteristics of a technology are
really different things. Even from a ‘technical’ viewpoint it
is by no means clear when the mosquito technology can be
said to work: does it mean diminishing the prevalence of
dengue? To what extent? Does “working” mean suppress-
ing the population of wildmosquitoes – if so, by howmuch,
for how long? Further research will be necessary to see
how the mosquitoes are made to work, under what sort of
geographical and economic conditions, and with what
types of political alliances.References
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